BTR Capital Management Inc. cut its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 13.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 24,457 shares of the biopharmaceutical company’s stock after selling 3,757 shares during the quarter. BTR Capital Management Inc.’s holdings in Gilead Sciences were worth $1,589,000 at the end of the most recent quarter.
A number of other large investors also recently added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD raised its position in Gilead Sciences by 0.8% in the second quarter. Price T Rowe Associates Inc. MD now owns 12,109,533 shares of the biopharmaceutical company’s stock valued at $818,120,000 after purchasing an additional 90,251 shares during the period. Parnassus Investments CA raised its position in Gilead Sciences by 13.3% in the third quarter. Parnassus Investments CA now owns 10,133,261 shares of the biopharmaceutical company’s stock valued at $642,246,000 after purchasing an additional 1,187,424 shares during the period. Nuveen Asset Management LLC raised its position in Gilead Sciences by 1,208.1% in the second quarter. Nuveen Asset Management LLC now owns 9,847,359 shares of the biopharmaceutical company’s stock valued at $665,288,000 after purchasing an additional 9,094,586 shares during the period. Morgan Stanley raised its position in Gilead Sciences by 10.7% in the second quarter. Morgan Stanley now owns 5,279,862 shares of the biopharmaceutical company’s stock valued at $356,708,000 after purchasing an additional 511,206 shares during the period. Finally, Sumitomo Mitsui Trust Holdings Inc. raised its position in Gilead Sciences by 1.1% in the third quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 5,155,214 shares of the biopharmaceutical company’s stock valued at $326,737,000 after purchasing an additional 54,910 shares during the period. 79.28% of the stock is currently owned by institutional investors.
NASDAQ:GILD traded down $0.21 during midday trading on Friday, hitting $62.99. 2,166,835 shares of the stock were exchanged, compared to its average volume of 6,689,442. The company has a market capitalization of $79.69 billion, a price-to-earnings ratio of 10.24, a P/E/G ratio of 3.90 and a beta of 1.11. Gilead Sciences, Inc. has a one year low of $60.89 and a one year high of $70.50. The business has a 50-day moving average price of $65.96 and a two-hundred day moving average price of $65.23. The company has a current ratio of 2.96, a quick ratio of 2.87 and a debt-to-equity ratio of 1.11.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, October 24th. The biopharmaceutical company reported $1.75 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.74 by $0.01. The company had revenue of $5.60 billion for the quarter, compared to analysts’ expectations of $5.61 billion. Gilead Sciences had a return on equity of 37.50% and a net margin of 12.04%. The firm’s revenue was up .1% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.84 earnings per share. Sell-side analysts forecast that Gilead Sciences, Inc. will post 6.63 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which was paid on Monday, December 30th. Shareholders of record on Friday, December 13th were issued a $0.63 dividend. The ex-dividend date of this dividend was Thursday, December 12th. This represents a $2.52 annualized dividend and a dividend yield of 4.00%. Gilead Sciences’s dividend payout ratio is currently 40.98%.
In other Gilead Sciences news, EVP Brett A. Pletcher sold 2,950 shares of the company’s stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $64.63, for a total value of $190,658.50. Following the transaction, the executive vice president now owns 20,014 shares of the company’s stock, valued at $1,293,504.82. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Brett A. Pletcher sold 4,000 shares of the company’s stock in a transaction on Friday, November 1st. The shares were sold at an average price of $64.52, for a total value of $258,080.00. Following the completion of the transaction, the executive vice president now directly owns 23,921 shares in the company, valued at approximately $1,543,382.92. The disclosure for this sale can be found here. Insiders sold 45,622 shares of company stock worth $2,986,438 in the last ninety days. 0.20% of the stock is owned by corporate insiders.
A number of brokerages have recently issued reports on GILD. BidaskClub lowered Gilead Sciences from a “sell” rating to a “strong sell” rating in a research report on Wednesday. Morgan Stanley set a $75.00 price objective on Gilead Sciences and gave the company a “hold” rating in a report on Friday, October 25th. Cowen reissued a “buy” rating and issued a $85.00 price objective on shares of Gilead Sciences in a report on Thursday, January 2nd. Guggenheim set a $86.00 price objective on Gilead Sciences and gave the company a “buy” rating in a report on Friday, October 25th. Finally, Cantor Fitzgerald lowered their price objective on Gilead Sciences from $88.00 to $85.00 and set an “overweight” rating for the company in a report on Friday, October 25th. Three equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Gilead Sciences currently has a consensus rating of “Hold” and an average price target of $78.91.
Gilead Sciences Company Profile
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
Read More: 52-Week High/Low Prices For Stock Selection
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.